HLB said it opened a new office in the Cambridge Innovation Center (CIC) in Boston, U.S. to bolster the collaboration and communication between HLB and its U.S. subsidiaries, such as Immunomic Therapeutics, while also supporting its group companies' entry into international markets.

HLB's new office opening comes after their selection by KHIDI (Korea Health Industry Development Institute) for the "K-Blockbuster Going Global Project."

The company stressed that the Boston office will play a pivotal role as HLB and its affiliates endeavor to discover and develop new drug technologies and materials in the global market.

Notably, the company plans to use the Boston outpost as a launchpad for potential future endeavors, including the acquisition of U.S. biotech companies or the incorporation of promising new pipelines.

"As HLB Group is making tangible achievements in various fields of drug development through its U.S. affiliates, we will continue to consider various measures to strengthen further the organic cooperation between domestic and overseas group companies and solidify our position as a global company," HLB US Head and Immunomic Therapeutics CEO Kim Dong-gun said.